Innovation in Cancer Care and Implications for Health Systems: Global Oncology Trend Report

In this report, we bring together the most comprehensive review of current trends in the oncology market, the state of innovation in therapeutics, measures of the value of treating cancer, and pricing trends.

Request the Report  

Summary

The intensifying global focus on oncology reflects its increasing impact on patients and expanding share of healthcare expenditure. Relative to other parts of the healthcare system, oncology brings high levels of uncertainty—in terms of the nature and rate of innovative treatments, the willingness by payers to reimburse care at current levels, and the shifting composition of the cancer patient population from mature and developed markets to low- and middle-income countries. As the sales of cancer treatments rise to $100 billion annually, more intensive scrutiny of this market can be expected and a deeper understanding of global oncology trends will be required by all stakeholders.

Featured Videos

Below, IMS Institute Executive Director Murray Aitken discusses six key findings in this report. Click here to view additional videos from this report.

Key Findings

Transformation of Oncology Treatment Modalities, 2003-2013

  • The top seven countries in the global market are leading the charge toward targeted therapies, ahead of the world as a whole
  • Targeted therapies such as MabThera/Rituxan, Avastin, and Herceptin truly represent the present and future of the oncology market
  • Pharmerging countries are lagging behind that of the top seven countries in share of targeted agents

While EU5 Relative to U.S. Ex-manufacturer Price is Extremely Variable, There is a Trend Towards Lower Pricing Over Time

  • Ex-manufacturer oncology prices in the E.U. vary widely, compared to U.S. prices
  • Even in scenarios where the E.U. ex-manufacturer price appears higher, it is likely not the final price paid considering the multitude of discount mechanisms in place in the E.U.
  • These discount mechanisms are enacted by payers at different levels in the E.U., allowing for a lower net price in these countries

Hospital Outpatient Costs Compared to Physician Office Costs

Note: All third party trademarks contained herein are the property of their respective owners and their use herein is for informational purposes and does not imply sponsorship or endorsement of their products or services.

  • Reimbursement levels for drug administration costs in hospital outpatient facilities are on average an incremental 189% of the level of physician office reimbursed costs for commercially insured patients under the age of 65 years
  • Higher costs in hospital outpatient facilities are incurred despite the increasing proportion of hospital systems that benefit from discounted drug pricing via 340B eligibility

Note: All third party trademarks contained herein are the property of their respective owners and their use herein is for informational purposes and does not imply sponsorship or endorsement of their products or services.

Please fill out the form below to request the Innovation in cancer care and implications for health system report:

 

Required*